Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Camrelizumab|DRUG: Liposomal Doxorubicin|DRUG: Losartan
Sponsor: Wuhan Union Hospital, China
Collaborators: Jiangsu HengRui Medicine Co., Ltd.|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.